Hualan Biological Vaccine Past Earnings Performance
Past criteria checks 4/6
Hualan Biological Vaccine's earnings have been declining at an average annual rate of -2.7%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 7.3% per year. Hualan Biological Vaccine's return on equity is 12.8%, and it has net margins of 35%.
Key information
-2.7%
Earnings growth rate
-6.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -7.3% |
| Return on equity | 12.8% |
| Net Margin | 35.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hualan Biological Vaccine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,300 | 805 | 999 | 81 |
| 31 Dec 23 | 2,410 | 860 | 1,040 | 91 |
| 30 Sep 23 | 1,984 | 645 | 859 | 96 |
| 30 Jun 23 | 915 | 330 | 285 | 103 |
| 31 Mar 23 | 1,956 | 614 | 856 | 128 |
| 01 Jan 23 | 1,826 | 520 | 805 | 135 |
| 30 Sep 22 | 1,997 | 598 | 856 | 146 |
| 30 Jun 22 | 2,879 | 948 | 1,207 | 148 |
| 31 Mar 22 | 1,833 | 624 | 640 | 148 |
| 01 Jan 22 | 1,830 | 621 | 649 | 144 |
| 30 Sep 21 | 2,608 | 1,004 | 1,015 | 146 |
| 30 Jun 21 | 2,441 | 922 | 960 | 155 |
| 31 Mar 21 | 2,439 | 934 | 960 | 125 |
| 31 Dec 20 | 2,426 | 925 | 959 | 111 |
| 31 Dec 19 | 1,049 | 375 | 346 | 73 |
| 31 Dec 18 | 803 | 270 | 381 | 53 |
| 31 Dec 17 | 285 | -77 | 216 | 64 |
Quality Earnings: 301207 has high quality earnings.
Growing Profit Margin: 301207's current net profit margins (35%) are higher than last year (31.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301207's earnings have declined by 2.7% per year over the past 5 years.
Accelerating Growth: 301207's earnings growth over the past year (30.9%) exceeds its 5-year average (-2.7% per year).
Earnings vs Industry: 301207 earnings growth over the past year (30.9%) exceeded the Biotechs industry -3.2%.
Return on Equity
High ROE: 301207's Return on Equity (12.8%) is considered low.